EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer

HU Yi; LIU Si-yang

doi:10.12019/j.issn.1671-5144.2017.01.013

HU Yi, LIU Si-yang. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013

Citation:

HU Yi, LIU Si-yang. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013

Citation:

HU Yi, LIU Si-yang. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer

HU Yi,
LIU Si-yang

Graphical Abstract

Abstract

FullText(HTML)

References (0)

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer

Catalog

Export File

Citation

Format

Content